Canton Biologics is a global contract development and manufacturing organization (CDMO) established in 2016, serving clients developing biologic medicines. The company specializes in monoclonal and bispecific antibodies, fusion proteins, and recombinant proteins, with capabilities spanning research and development through GMP manufacturing. Its services include antibody discovery, developability assessment, cell-line and process development, analytical methods, technology transfer, drug-substance and drug-product manufacturing, process characterization and validation, quality control, regulatory affairs, and project management.

Canton Biologics also offers technology platforms for cell-line development, process development, purification, membrane chromatography, and high-concentration formulation. Its manufacturing network includes facilities in China and a research and development center in Berlin, Germany. The company states that its quality systems comply with FDA, EMA, and NMPA standards and support IND submissions. In addition to biologics, its listed capabilities include microbial production and advanced therapy-related modalities such as oncolytic viruses, CAR-T, live biotherapeutic products, and exosomes. Canton Biologics positions itself as a partner for organizations seeking technical expertise, integrated development services, and manufacturing support across biologic programs.